Format

Send to

Choose Destination
Clin J Am Soc Nephrol. 2019 May 7;14(5):664-672. doi: 10.2215/CJN.12201018. Epub 2019 Apr 18.

Major Adverse Kidney Events in Pediatric Sepsis.

Author information

1
Departments of Anesthesiology and Critical Care and WeissS@Email.chop.edu.
2
Pediatric Sepsis Program at the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
3
Center for Mitochondrial and Epigenomic Medicine at the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
4
Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
5
Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and.
6
Children's Hospital Association, Lenexa, Kansas.
7
Departments of Anesthesiology and Critical Care and.

Abstract

BACKGROUND AND OBJECTIVES:

Major adverse kidney events, a composite of death, new kidney replacement therapy, or persistent kidney dysfunction, is a potential patient-centered outcome for clinical trials in sepsis-associated kidney injury. We sought to determine the incidence of major adverse kidney events within 30 days and validate this end point in pediatric sepsis.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:

We conducted a retrospective observational study using the Pediatric Health Information Systems Plus database of patients >6 months to <18 years old with a diagnosis of severe sepsis/septic shock; orders for bacterial blood culture, antibiotics, and at least one fluid bolus on hospital day 0/1; and known hospital disposition between January 2007 and December 2011. The primary outcome was incidence of major adverse kidney events within 30 days. Major adverse kidney events within 30 days were validated against all-cause mortality at hospital discharge, hospital length of stay, total hospital costs, hospital readmission within 30 days and 1 year, and lowest eGFR between 3 months and 1 year after discharge. We reported incidence of major adverse kidney events within 30 days with 95% confidence intervals using robust SEM and used multivariable logistic regression to test the association of major adverse kidney events within 30 days with hospital costs and mortality.

RESULTS:

Of 1685 admissions, incidence of major adverse kidney events within 30 days was 9.6% (95% confidence interval, 8.1% to 11.0%), including 4.5% (95% confidence interval, 3.5% to 5.4%) death, 1.7% (95% confidence interval, 1.1% to 2.3%) kidney replacement therapy, and 5.8% (95% confidence interval, 4.7% to 6.9%) persistent kidney dysfunction. Patients with versus without major adverse kidney events within 30 days had higher all-cause mortality at hospital discharge (28% versus 1%; P<0.001), higher total hospital costs ($61,188; interquartile range, $21,272-140,356 versus $28,107; interquartile range, $13,056-72,697; P<0.001), and higher proportion with eGFR<60 ml/min per 1.73 m2 between 3 months and 1 year after discharge (19% versus 4%; P=0.001). Major adverse kidney events within 30 days was not associated with length of stay or readmissions.

CONCLUSIONS:

In children with sepsis, major adverse kidney events within 30 days are common, feasible to measure, and a promising end point for future clinical trials.

KEYWORDS:

Anti-Bacterial Agents; Blood Culture; Confidence Intervals; Health Information Systems; Hospital Costs; Incidence; Inpatients; Kidney Replacement Therapy; Length of Stay; Logistic Models; Patient Discharge; Patient Readmission; Retrospective Studies; Sepsis; Shock, Septic; acute kidney failure; clinical trial; glomerular filtration rate; outcomes; pediatrics

PMID:
31000518
PMCID:
PMC6500940
[Available on 2020-05-07]
DOI:
10.2215/CJN.12201018

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center